慢性乙型肝炎的治疗现状与中医药“免疫孵育”策略的实践  

Treatments for chronic hepatitis B and the practice of"immune incubation"strategy with traditional Chinese medicine

作　　者：叶永安[1,2] YE Yong-an(Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing,10070,China)

机构地区：[1]北京中医药大学东直门医院,北京100700 [2]北京中医药大学肝病研究所

出　　处：《中西医结合肝病杂志》2021年第2期97-101,共5页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：国家科技重大专项“十三五”课题(No.2018ZX10725505)。

摘　　要：慢性乙型肝炎是关系中国民生的重大传染性疾病,针对该病的中药及西药抗病毒治疗各有不可替代的优势和局限性。近年学界对治疗策略和终点选择有新观点,强调宿主免疫因素在转归中的主导作用,并对有限疗程的抗病毒治疗持更开放的态度。中医药“免疫孵育”策略是北京中医药大学团队在“十五”期间构想,依托“十一五”课题首次临床验证,并在“十二五”期间进一步完善的治疗策略,可服务于提升宿主免疫控制水平及降低停药复发的关键临床问题。该文对治疗的国际前沿、关键瓶颈等热点话题进行讨论,并回顾“免疫孵育”策略的发展历程,为临床治疗提供新思路。Chronic hepatitis B(CHB)is a major infectious disease that has enormous impact on the livelihood of China,meanwhile the antiviral treatments with either herbal or nucleos(t)ide analogues(NAs)have irreplaceable advantages and limitations.In recent years,new insights have emerged about treatment strategies and endpoints,including the dominant role of host immunity in prognosis,as well as a more open attitude toward restricted NAS therapies.The TCM‘immune incubation’strategy was developed by our team during the 10 th Five year Plan project,first clinically validated by the 11 th Five Year Plan study,and further refined during the 12 th Five Year Plan project.It could serve the key point of improving host immune control against the virus,and reducing relapse after NAs withdrawal.This manuscript discussed international frontier research topics and treatment bottlenecks for CHB,reviewed the development of the‘immune incubation’strategy,and shared our ideas for overcoming obstacles in clinical treatments.

关 键 词：肝炎 乙型 慢性 免疫孵育 治疗现状 

分 类 号：R512.62[医药卫生—内科学]